| Target Price | ¥550.80 |
| Price | ¥516.00 |
| Potential |
6.74%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Jcr Pharmaceuticals Co.,ltd. 2027 .
The average Jcr Pharmaceuticals Co.,ltd. target price is ¥550.80.
This is
6.74%
register free of charge
¥945.00
83.14%
register free of charge
¥454.50
11.92%
register free of charge
|
|
| A rating was issued by 11 analysts: 4 Analysts recommend Jcr Pharmaceuticals Co.,ltd. to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Jcr Pharmaceuticals Co.,ltd. stock has an average upside potential 2027 of
6.74%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 40.32 | 44.47 |
| 21.91% | 10.28% | |
| EBITDA Margin | 1.38% | 8.61% |
| 106.85% | 525.49% | |
| Net Margin | 5.40% | 0.65% |
| 137.54% | 87.97% |
8 Analysts have issued a sales forecast Jcr Pharmaceuticals Co.,ltd. 2027 . The average Jcr Pharmaceuticals Co.,ltd. sales estimate is
This results in the following potential growth metrics:
8 Jcr Pharmaceuticals Co.,ltd. Analysts have issued a net profit forecast 2027. The average Jcr Pharmaceuticals Co.,ltd. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 17.86 | 2.36 |
| 146.47% | 86.79% | |
| P/E | 219.08 | |
| EV/Sales | 2.43 |
8 Analysts have issued a Jcr Pharmaceuticals Co.,ltd. forecast for earnings per share. The average Jcr Pharmaceuticals Co.,ltd. EPS is
This results in the following potential growth metrics and future valuations:
Jcr Pharmaceuticals Co.,ltd....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


